Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/20/25
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 10/06/23
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 11/30/22
End: 12/31/24
Due: 12/31/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19) | NCT05387278 | Vitti Labs, LLC | user2@example.com | None | 2025-03-20 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI) | NCT06072794 | Vitti Labs, LLC | user2@example.com | None | 2023-10-06 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19 | NCT05387239 | Vitti Labs, LLC | user2@example.com | None | 2022-11-30 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |